Inactive Instrument

Other languages Axovant Sciences Ltd Nasdaq

Equities

BMG0750W1047

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14
Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours	22-12-14
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10
Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11
Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-14
Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-06-14
Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value	22-04-26
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11
Health Care Stocks Back Near Even For Tuesday Trading	22-02-01
Sector Update: Health Care	22-02-01
Sio Gene Therapies Ends Gene Therapy Program for Parkinson's Disease, Names New CEO	22-02-01
Sio Gene Therapies Terminates Oxford Biomedica's Parkinson's Disease Gene Therapy Program	22-02-01
Sio Gene Therapies Inc. Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis	22-01-31
Sio Gene Therapies Inc. Announces Executive Changes	22-01-31
Sio Gene Therapies Inc. Appoints David Nassif, J.D. to Its Board of Directors	22-01-31
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12
Sio Gene Receives US Food and Drug Administration's Fast Track Designation for GM2 Gangliosidosis Gene Therapy	21-11-01
Sio Gene Therapies : Chief Research and Development Officer Gavin Corcoran to Leave Next Month; Unveils Chief Medical Officer Role	21-10-21
Sio Gene Therapies : Health Care Stocks Little Changed Despite Moderate Rise by Biotechs	21-10-21
Sio Gene Therapies : Secures FDA Fast Track Designation for Gene Therapy Candidate for GM1 Gangliosidosis	21-10-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Axovant Sciences Ltd Nasdaq

Equities

BMG0750W1047

Other languages

Filters